Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10332)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 8, 2016 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Okamoto T, Koda M, Miyoshi K, Onoyama T, Kishina M, Matono T, Sugihara T, Hosho K, Okano J, Isomoto H, Murawaki Y. Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model. World J Hepatol 2016; 8(22): 933-941 [PMID: 27574547 DOI: 10.4254/wjh.v8.i22.933] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v8/i22/933.htm |
| Number | Citing Articles |
| 1 |
Francesca Schinzari, Carmine Cardillo. Intricacies of the endothelin system in human obesity: role in the development of complications and potential as a therapeutic target. Canadian Journal of Physiology and Pharmacology 2020; 98(9): 563 doi: 10.1139/cjpp-2019-0651
|
| 2 |
Osvaldo Rivera-Gonzalez, Natalie A. Wilson, Laura E. Coats, Erin B. Taylor, Joshua S. Speed. Endothelin receptor antagonism improves glucose handling, dyslipidemia, and adipose tissue inflammation in obese mice. Clinical Science 2021; 135(14): 1773 doi: 10.1042/CS20210549
|
| 3 |
Guillermo A. Ortiz, Guadalupe Garcia-Tsao. Future Pharmacological Therapies of Portal Hypertension. Current Hepatology Reports 2019; 18(1): 36 doi: 10.1007/s11901-019-00448-2
|
| 4 |
Stefania Cannito, Erica Novo, Maurizio Parola. Therapeutic pro-fibrogenic signaling pathways in fibroblasts. Advanced Drug Delivery Reviews 2017; 121: 57 doi: 10.1016/j.addr.2017.05.017
|
| 5 |
Henrik H. Hansen, Michael Feigh, Sanne S. Veidal, Kristoffer T. Rigbolt, Niels Vrang, Keld Fosgerau. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discovery Today 2017; 22(11): 1707 doi: 10.1016/j.drudis.2017.06.007
|
| 6 |
Meng Li, Man Cui, Guoxia Li, Yueqiu Liu, Yunsheng Xu, Seyed Parsa Eftekhar, Moein Ala. The Pathophysiological Associations Between Obesity, NAFLD, and
Atherosclerotic Cardiovascular Diseases. Hormone and Metabolic Research 2024; 56(10): 683 doi: 10.1055/a-2266-1503
|
| 7 |
Hongshan Li, Hao Ying, Airong Hu, Yaoren Hu, Dezhou Li. Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis <i>via</i> Regulating Hepatic Lipogenesis and Fatty Acid Oxidation. Biological & Pharmaceutical Bulletin 2017; 40(5): 650 doi: 10.1248/bpb.b16-00942
|
| 8 |
Jie Wang, Lili An, Yun Zhao, Cheng Zhang, Shengnan Li, Chen Ye, Shuqian Jing, Haiying Hang. In vitro affinity maturation of antibody against membrane-bound GPCR molecules. Applied Microbiology and Biotechnology 2019; 103(18): 7703 doi: 10.1007/s00253-019-10030-x
|
| 9 |
Li Feng, Songhua Wang, Feng Chen, Cheng Zhang, Qiao Wang, Yuting Zhao, Zifeng Zhang. Hepatic Knockdown of Endothelin Type A Receptor (ETAR) Ameliorates Hepatic Insulin Resistance and Hyperglycemia Through Suppressing p66Shc-Mediated Mitochondrial Fragmentation in High-Fat Diet-Fed Mice. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021; : 963 doi: 10.2147/DMSO.S299570
|
| 10 |
Calen A. Steiner, Peter D. R. Higgins. Fibrostenotic Inflammatory Bowel Disease. 2018; : 347 doi: 10.1007/978-3-319-90578-5_23
|